Theravance Biopharma (NASDAQ:TBPH) Rating Lowered to “Hold” at Zacks Research

Theravance Biopharma (NASDAQ:TBPH) was downgraded by equities researchers at Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Monday, Zacks reports.

Several other equities analysts also recently commented on the company. HC Wainwright downgraded Theravance Biopharma from a “buy” rating to a “neutral” rating and upped their price objective for the company from $15.00 to $17.00 in a research report on Tuesday, July 7th. Weiss Ratings upgraded Theravance Biopharma from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday, August 17th. BTIG Research lowered shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a research note on Monday, June 29th. JonesTrading cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Monday, June 29th. Finally, Wall Street Zen downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Eight equities research analysts have rated the stock with a Hold rating, According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $19.40.

Theravance Biopharma Price Performance

Theravance Biopharma stock opened at $17.06 on Monday. The firm has a market capitalization of $885.76 million, a P/E ratio of 16.89 and a beta of 0.25. Theravance Biopharma has a 1-year low of $13.08 and a 1-year high of $21.03. The company’s 50-day moving average is $16.95 and its 200 day moving average is $16.49.

Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.18). Theravance Biopharma had a net margin of 51.58% and a negative return on equity of 0.77%. The business had revenue of $20.73 million for the quarter, compared to analysts’ expectations of $22.49 million. Research analysts anticipate that Theravance Biopharma will post 1.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 13,314 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $16.39, for a total value of $218,216.46. Following the completion of the sale, the senior vice president directly owned 232,457 shares in the company, valued at approximately $3,809,970.23. This represents a 5.42% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Eli Samaha sold 273,871 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $17.23, for a total value of $4,718,797.33. Following the transaction, the insider directly owned 9,237,279 shares in the company, valued at $159,158,317.17. The trade was a 2.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 350,011 shares of company stock worth $6,008,309 over the last 90 days. 7.65% of the stock is currently owned by company insiders.

Institutional Trading of Theravance Biopharma

Several institutional investors and hedge funds have recently made changes to their positions in the company. Quarry LP bought a new position in Theravance Biopharma during the 3rd quarter worth about $26,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of Theravance Biopharma by 107.4% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 1,411 shares in the last quarter. CIBC Private Wealth Group LLC lifted its position in shares of Theravance Biopharma by 20,269.6% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 4,662 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of Theravance Biopharma by 18.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 781 shares during the period. Finally, Virtus Advisers LLC purchased a new stake in shares of Theravance Biopharma in the 4th quarter worth approximately $170,000. 99.10% of the stock is currently owned by institutional investors.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.